» Articles » PMID: 7904314

P53 Oncogene Mutations in Human Prostate Cancer Specimens

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 1994 Feb 1
PMID 7904314
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Eighty-five prostate cancer specimens from prostate resections were analyzed for the presence of p53 gene mutations by immunohistochemical staining for P53 protein. DNA from thirty-four of these samples was also analyzed for mutations in exons 5-8 by single-strand chain polymorphism (SSCP) analysis. One sample had P53 staining by immunohistochemistry, one sample was positive for a p53 mutation by SSCP, and one sample was positive by both techniques. Mutations in the two samples that were positive by SSCP were confirmed by nucleotide sequencing. In a separate study of ten lymph nodes that contained prostate cancer metastases, one had detectable P53 protein by immunohistochemical staining. Therefore, p53 mutations appear to be low frequency events in primary prostate cancer.

Citing Articles

Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.

Dovey Z, Nair S, Chakravarty D, Tewari A Cancer Rep (Hoboken). 2021; 4(5):e1340.

PMID: 33599076 PMC: 8551995. DOI: 10.1002/cnr2.1340.


TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.

Al Zoubi M, Otoum R, Alorjani M, Al Bashir S, Al Trad B, Abualrja M Asian Pac J Cancer Prev. 2020; 21(11):3365-3371.

PMID: 33247697 PMC: 8033120. DOI: 10.31557/APJCP.2020.21.11.3365.


Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.

He Y, Johnson D, Yang J, Wu H, You S, Yoon J Oncogene. 2019; 38(38):6507-6520.

PMID: 31358900 PMC: 6752978. DOI: 10.1038/s41388-019-0901-8.


Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.

Leighton X, Bera A, Eidelman O, Bubendorf L, Zellweger T, Banerjee J PLoS One. 2018; 13(10):e0205837.

PMID: 30321230 PMC: 6188866. DOI: 10.1371/journal.pone.0205837.


Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells.

Chopra H, Khan Z, Contreras J, Wang H, Sedrak A, Zhu Y Oncotarget. 2018; 9(5):6270-6281.

PMID: 29464071 PMC: 5814211. DOI: 10.18632/oncotarget.23569.